Stock prices of CNS Pharmaceuticals, which develops treatments for cancers of the brain and central nervous system, plunged 35% on Wednesday, reaching an all-time low. The company announced the price at which it will sell its shares to private investors. The figure turned out to be a third lower than previously stated, and the volume was higher, which will significantly dilute the stakes of existing shareholders.
Details
CNS Pharmaceuticals’ stock prices plummeted 35.2% to $1.84 on Nasdaq on Wednesday, June 26. This is the lowest the company’s stock has ever traded on the exchange. After the...